

DISCOVER THE **YIMMUGO[®]** **DIFFERENCE**

A modern IVIG that delivers what
you need for a life in motion^{1,2}:

PROTECTION
against infections

TOLERABILITY
with a low chance of headache

PRECISION
with manufacturing that treats
antibodies with care

Yimmugo[®]
Immune Globulin Intravenous,
Human-dira, 10% Liquid

WHAT IS YIMMUGO[®]?

YIMMUGO (immune globulin intravenous, human – dira) is an immune globulin (Ig) liquid used to treat primary humoral immunodeficiency in people 2 years of age and older.

IMPORTANT SAFETY INFORMATION

YIMMUGO may cause:

- Blood clots (thrombosis). Blood clots may occur in people taking Ig intravenous (IGIV) products, including YIMMUGO. You may be at greater risk for blood clots if you are older, sit or lie for long periods, have a clotting condition or a history of blood clots, take estrogen, have a central catheter, have thick blood, and/or if you have other conditions that put you at risk for cardiovascular disease. Blood clots may occur even if you do not have any of these risk factors. Your healthcare provider should monitor you for signs and symptoms of blood clotting.
- Impaired kidney function or kidney failure. IGIV products, particularly those that contain sugar (sucrose), have been associated with kidney dysfunction and damage, kidney failure, and death. Kidney damage and failure are more common in people receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. You may be at greater risk for kidney failure if you have kidney disease, diabetes, are seriously dehydrated, overweight, take drugs that may damage your kidneys, or are over age 65. Your healthcare provider should monitor your kidney function before and periodically after your first infusion.

IVIG, intravenous immune globulin.

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.

Kedrion
Biopharma

WELCOME

Whether you are new to **intravenous immune globulin treatment** or are switching from a different treatment, the information in this brochure will help you get started with YIMMUGO®.

TABLE OF CONTENTS

What is primary immunodeficiency?

3

Starting YIMMUGO

7

What is YIMMUGO?

4

Support & resources

8

Safety & side effects

5

Glossary

10

What makes YIMMUGO different?

6

Commonly asked questions

11

This brochure provides information about YIMMUGO but is not a substitute for medical advice.

IMPORTANT SAFETY INFORMATION (cont'd)

Do NOT use YIMMUGO if:

- You have a history of severe hypersensitivity or a history of allergic reactions to human Ig. Tell your healthcare provider if you have had a serious reaction to other medicines that contain human Ig or ask if you are not sure.
- You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, or have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.

WHAT IS primary immunodeficiency?

Primary immunodeficiency (PI) is a group of more than 550 rare, **chronic conditions** in which part of the body's immune system is missing or does not function correctly. PI can affect anyone regardless of gender, age, or race.³

People with PI do not have enough functioning **antibodies** to fight infections and rely on immune globulin treatments for protection against infection.⁴

People living with PI may experience symptoms like⁵:

- Recurrent bacterial and viral infections
- **Thrush**
- Recurrent **sinopulmonary infections**
- Diarrhea
- **Hypoparathyroidism**
- Poor wound healing
- Skin infections
- Bone fragility



Immune globulin treatments are the standard of care for most people with PI.⁴

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS

- Severe allergic reactions may occur. People with IgA deficiency who have antibodies against IgA may be at greater risk of these reactions.

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.

What is YIMMUGO® and how can it help?

YIMMUGO (imm • YOO • go) is an FDA-approved IVIG used to treat patients with primary immunodeficiency (PI). YIMMUGO was studied in a [clinical trial](#) to see how safe and effective it was for children and adults with PI. The clinical trial lasted for approximately 1 year and included 67 people aged 2 to 75 years.¹

The trial evaluated how many [serious bacterial infections \(SBIs\)](#) people across all age groups had in 1 year when treated with YIMMUGO.¹

How effective is YIMMUGO?



Patients receiving YIMMUGO experienced on average¹:

0.07 SBIs per person per year across all age groups

In a clinical trial, people treated with YIMMUGO had **less than 1 SBI per year** on average, no matter their age.¹

Less down time was seen with YIMMUGO^{1*}

The study also looked at the impact of infections on daily life¹:



6 days
lost from work/school due to infection



<1/2 a day
in the hospital due to infection per person per year



2.7
other infections per person per year

Proven protection when you need it most

*On average, people living with PI missed about 34 days of school each year and spent nearly 20 days in the hospital. These findings came from doctors who cared for 119 patients participating in a special genetic testing program across 21 medical centers.⁶

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- Blood damage called hemolysis and hemolytic anemia can develop after treatment with YIMMUGO. Your healthcare provider should monitor you for signs and symptoms.

What are the potential side effects with YIMMUGO?

Be sure to tell your doctor right away about any side effects you may be experiencing with YIMMUGO. The safety of YIMMUGO was studied in a clinical trial, and the results showed that most side effects were considered mild to moderate.¹

Headaches were the most common side effect for people taking YIMMUGO.¹



Only 2%
of infusions were associated with headaches.¹

Other common side effects that were seen in less than 1% of infusions included¹:

- Upper respiratory tract infections
- Nausea
- Fatigue
- Increased blood pressure

There were 2 serious side effects related to YIMMUGO occurring in 2 patients.^{1*}

Talk to your doctor if you have any questions regarding the safety of YIMMUGO or if you experience any side effects after an infusion.

*Two patients experienced anaphylactic reaction and severe neutropenia, both were serious side effects that led to ending treatment with YIMMUGO.¹

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- If you are at risk of developing kidney damage or failure, your healthcare provider should monitor your kidney function before and periodically after your first infusion.

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.


What makes YIMMUGO® different?

YIMMUGO uses VIBROMIX technology during a key purification step in its manufacturing process designed to help protect antibodies.²



What is VIBROMIX technology and how does it help?²

- VIBROMIX technology mixes antibodies more gently than traditional manufacturing methods
- Each vial of YIMMUGO contains antibodies that are believed to be whole, undamaged, and functional, which may help reduce the risk of unwanted side effects*



Not actual size.



Why are antibodies important?

All immune globulin treatments are made up of Y-shaped proteins, known as antibodies, that protect you against bacteria and viruses. It's important that these infection-fighting antibodies do not break apart during manufacturing so they can be passed to you.^{2,4,7}

Why is it important to treat antibodies with care?

Having a buildup of broken antibodies during the manufacturing process may lead to unwanted immune responses and side effects.²

*YIMMUGO has not been directly compared to other IVIG products in studies. There have also not been any studies comparing traditional mixing methods to vibromixing.²

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- You could experience higher-than-normal levels of protein in your blood, thick blood, or low sodium (salt) in your blood. This may prevent your blood from flowing easily and possibly lead to blood clots.

What should I know before starting YIMMUGO?

YIMMUGO is given through **intravenous infusion** by a trained healthcare professional at an infusion center or in the comfort of your home every 3 to 4 weeks.¹

Your dose and how often you get infusions can change depending on your weight and how well you respond to YIMMUGO.¹

You will want to dress comfortably for your infusion, but once you're there, you're welcome to pass the time by:



Listening to music or a podcast



Reading



Watching a TV show or movie



Playing a game



Catching up on work



Relaxing

It's important to drink plenty of water before your infusion with YIMMUGO.¹

After your infusion, the nurse who administered YIMMUGO will have you wait to see how you're feeling.¹



Keep track of how you feel after each infusion to help you and your doctor decide if your dose of YIMMUGO needs to be adjusted.¹

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- Brain swelling called aseptic meningitis syndrome may occur infrequently with IGIV products, especially if you receive a high dose or a rapid infusion.

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.

Patient support is available at every step of your journey



How do I get YIMMUGO®?

YIMMUGO is available through a network of **specialty pharmacies**.

Your doctor or infusion center will help you find a specialty pharmacy that offers YIMMUGO.

Coverage assistance for YIMMUGO

Kedrion Biopharma provides reimbursement support for patients receiving YIMMUGO.

This support includes:

- Patient-specific benefit verifications
- Payer coverage and coding research
- Assistance with copay and claims questions
- Appeal support for denied prior authorization or claims

For more questions about receiving YIMMUGO, coverage assistance, reimbursement support, and more, call the Kedrion information line: **888-262-8040** or email **reimbursementsupport@medmonk.com**

How can I connect with others?

The following list of patient advocacy groups can help support you on your journey with primary immunodeficiency (PI).



The Immune Deficiency Foundation (IDF) improves the diagnosis, treatment, and quality of life for every person affected by PI. The IDF fosters a community that is connected, engaged, and empowered through advocacy, education, and research.

Learn more at primaryimmune.org



The Jeffrey Modell Foundation is a global nonprofit dedicated to early diagnosis, meaningful treatments and, ultimately, cures through basic and clinical research, physician and patient education, public awareness, government advocacy, patient support, newborn screening, and genetic sequencing. **Learn more at info4pi.org**



The International Patient Organisation for Primary Immunodeficiencies (IPOPI) is an international nonprofit organization and the leading worldwide advocate for people with PI. **Learn more at ipopi.org**



The Immunoglobulin National Society (IgNS) is a professional organization dedicated to the advancement of Ig therapy practice across clinical indications and areas of practice. **Learn more at ig-ns.org**

IMPORTANT SAFETY INFORMATION (cont'd)

WARNINGS AND PRECAUTIONS (cont'd)

- Swelling of the lungs may occur following treatment. Your healthcare provider should monitor you for signs of lung damage.

What is YIMMUGO®?

YIMMUGO (immune globulin intravenous, human – dira) is an immune globulin (Ig) liquid used to treat primary humoral immunodeficiency in people 2 years of age and older.

IMPORTANT SAFETY INFORMATION

YIMMUGO may cause:

- **Blood clots (thrombosis).** Blood clots may occur in people taking Ig intravenous (IGIV) products, including YIMMUGO. You may be at greater risk for blood clots if you are older, sit or lie for long periods, have a clotting condition or a history of blood clots, take estrogen, have a central catheter, have thick blood, and/or if you have other conditions that put you at risk for cardiovascular disease. Blood clots may occur even if you do not have any of these risk factors. Your healthcare provider should monitor you for signs and symptoms of blood clotting.
- **Impaired kidney function or kidney failure.** IGIV products, particularly those that contain sugar (sucrose), have been associated with kidney dysfunction and damage, kidney failure, and death. Kidney damage and failure are more common in people receiving IGIV products containing sucrose. YIMMUGO does not contain sucrose. You may be at greater risk for kidney failure if you have kidney disease, diabetes, are seriously dehydrated, overweight, take drugs that may damage your kidneys, or are over age 65. Your healthcare provider should monitor your kidney function before and periodically after your first infusion.

Do NOT use YIMMUGO if:

- You have a history of severe hypersensitivity or a history of allergic reactions to human Ig. Tell your healthcare provider if you have had a serious reaction to other medicines that contain human Ig or ask if you are not sure.
- You have an immunoglobulin A (IgA) deficiency, have antibodies to IgA, or have a hypersensitivity or a history of allergic reactions. Tell your healthcare provider if you have an IgA deficiency or ask if you are not sure.

WARNINGS AND PRECAUTIONS

- Severe allergic reactions may occur. People with IgA deficiency who have antibodies against IgA may be at greater risk of these reactions.
- Blood damage called hemolysis and hemolytic anemia can develop after treatment with YIMMUGO. Your healthcare provider should monitor you for signs and symptoms.
- You could experience higher-than-normal levels of protein in your blood, thick blood, or low sodium (salt) in your blood. This may prevent your blood from flowing easily and possibly lead to blood clots.
- Brain swelling called aseptic meningitis syndrome may occur infrequently with IGIV products, especially if you receive a high dose or a rapid infusion.
- Swelling of the lungs may occur following treatment. Your healthcare provider should monitor you for signs of lung damage.
- YIMMUGO is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.
- Be sure to tell your healthcare provider about your recent history of vaccinations. Live vaccines for diseases like measles, mumps, rubella, and varicella may not work as well while receiving YIMMUGO. Tell your healthcare provider that you are taking YIMMUGO before you receive any vaccination.

ADVERSE REACTIONS

The most common side effects of YIMMUGO were headache, upper respiratory tract infections, fatigue, nausea, and increased blood pressure. During treatment with YIMMUGO, be sure to tell your healthcare provider about any unusual symptoms you experience, as they may indicate a possible side effect.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see enclosed full Prescribing Information for full prescribing details, including Boxed Warning.

A

Antibodies: proteins, created by your immune system, that protect you when an unwanted substance, like a bacteria or virus, enters your body

C

Chronic conditions: conditions that last 1 year or more and may require both ongoing medical attention and limited activities of daily living

Clinical trial: a research study that evaluates new interventions, like tests or treatments, and their effect on a person’s health

H

Hypoparathyroidism: a rare condition that causes low levels of calcium in your blood

I

Intravenous immune globulin (IVIG) treatment: an infusion treatment created from donated antibodies to manage immunodeficiency disorders

Intravenous (IV) infusion: a method of putting fluids, including drugs, into the bloodstream

S

Serious bacterial infections (SBIs): infections considered to be serious over 12 months in the YIMMUGO® clinical trial, including bacterial pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, visceral abscesses, or bacterial meningitis¹

Sinopulmonary infections: infections that affect your sinuses and lungs

Specialty pharmacies: pharmacies that focus on high-cost, high-touch medication therapy for patients with complex disease states

Standard of care: treatment that is accepted and used by healthcare professionals as a proper treatment for a certain type of disease

T

Thrush: a fungal infection that can grow in your mouth, throat, and other parts of your body

Here are a few commonly asked questions about YIMMUGO®. Talk to your doctor about any additional questions you may have based on your treatment needs.



How active can I be while taking YIMMUGO?

Some people may find it helpful to stay active while taking YIMMUGO. Talk to your doctor about how you are feeling so that, together, you can come up with an exercise routine that works best for you.



Is there anything I should bring to my infusion?

You should bring water to make sure you stay hydrated before your infusion and dress comfortably.¹

Since your infusion time may vary, it’s important that you have what you need to be comfortable. You can bring something to help you pass the time, whether it’s a tablet to watch a show on, headphones to listen to music or a podcast, a book, a laptop to catch up on work, or a cozy pillow and blanket to help you relax.



What are the most common side effects of YIMMUGO?

The most common side effect of YIMMUGO in the clinical trial was headache. Other common side effects included upper respiratory infections, nausea, fatigue, and increased blood pressure.¹



Does YIMMUGO impact fertility?

There are no data on how YIMMUGO impacts fertility.¹ Talk to your doctor if you have specific concerns about fertility, being pregnant, or breastfeeding while taking YIMMUGO.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

- YIMMUGO is made from human blood and may contain infectious agents, eg, viruses and, theoretically, the Creutzfeldt-Jakob disease agent.

IMPORTANT SAFETY INFORMATION (cont’d)

WARNINGS AND PRECAUTIONS (cont’d)

- Be sure to tell your healthcare provider about your recent history of vaccinations. Live vaccines for diseases like measles, mumps, rubella, and varicella may not work as well while receiving YIMMUGO. Tell your healthcare provider that you are taking YIMMUGO before you receive any vaccination.

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.

DISCOVER THE YIMMUGO[®] DIFFERENCE

A modern IVIG that delivers what
you need for a life in motion^{1,2}:

PROTECTION
against infections

TOLERABILITY
with a low chance of headache

PRECISION
with manufacturing that treats
antibodies with care

Yimmugo[®]
Immune Globulin Intravenous,
Human-dlra, 10% Liquid

Visit YIMMUGO.us
to learn more.



IMPORTANT SAFETY INFORMATION (cont'd)

ADVERSE REACTIONS

The most common side effects of YIMMUGO were headache, upper respiratory tract infections, fatigue, nausea, and increased blood pressure. During treatment with YIMMUGO, be sure to tell your healthcare provider about any unusual symptoms you experience, as they may indicate a possible side effect.

To report SUSPECTED ADVERSE REACTIONS, contact Kedrion Biopharma Inc. at 1-855-3KDRION (1-855-353-7466) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

References: 1. YIMMUGO [prescribing information]. Kedrion Biopharma Inc.; 2024. 2. Duellberg C, Hannappel A, Kistner S, Maneg O. Biochemical characterization of a new 10% IVIG preparation [IgG Next Generation (BT595)/Yimmugo[®]] obtained from a manufacturing process preserving IgA/IgM potential of human plasma. *Drugs R D*. 2023;23(3):245-255. 3. Immune Deficiency Foundation. What is PI? Accessed April 25, 2025. <https://primaryimmune.org/understanding-primaryimmunodeficiency/what-is-pi> 4. Immune Deficiency Foundation. Immunoglobulin replacement therapy. Accessed April 25, 2025. <https://primaryimmune.org/understanding-primary-immunodeficiency/treatment/immunoglobulin-replacement-therapy> 5. McCusker C, Upton J, Warrington R. Primary immunodeficiency. *Allergy Asthma Clin Immunol*. 2018;14(suppl 2):61. 6. Quinn J, Modell V, Holle J, et al. Jeffrey's insights: Jeffrey Modell Foundation's global genetic sequencing pilot program to identify specific primary immunodeficiency defects to optimize disease management and treatment. *Immunol Res*. 2020;68(3):126-134. 7. Cleveland Clinic. Antibodies. Content last reviewed on May 6, 2022. Accessed April 25, 2025. <https://my.clevelandclinic.org/health/body/22971-antibodies>

Please see the full Important Safety Information on page 9 and the enclosed full Prescribing Information, including Boxed Warning.

© 2025 Kedrion Biopharma Inc. All rights reserved.
YIMMUGO is a registered trademark and the YIMMUGO logo is a trademark of Biotest AG.
YIM.0006.USA.25 July 2025

Kedrion
Biopharma